← All stocks

MYRIAD GENETICS INC

MYGN Net selling
CIK 0000899923 #3557 in the set updated 19 Sep 2026
Bought (120 mo)
$1.40M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$80.49M
$3.52M on a plan · $64.15M straight out of an exercise
Sold at will
$12.83M
35 of 122 sales
Net
−$79.10M
−$11.43M against sales at will

By person

44 insiders · 135 transactions
5.5×

Samraat S. Raha holds 5.5 times base salary in stock. $4.76M of shares against $856.90K in salary for 2025.

Salary from the company's own proxy. The shares are what Samraat S. Raha last reported holding, valued at $4.46, the price Common Stock was last bought or sold at on the open market here, on 8 Jun 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
LANCHBURY JERRY S
See Remarks
$24.83M (34) scheduled
−$24.83M
264,324
0.2763%
$1.18M
+135.3%
Capone Mark Christopher
President & C.E.O.
$12.73M (7) scheduled
−$12.73M
522,216
0.5460%
$2.33M
+141.0%
MARSH RICHARD M
E.V.P., General Counsel
$9.15M (7) scheduled
−$9.15M
144,174
0.1507%
$642.47K
+30.9%
DIAZ PAUL J
President and CEO
$6.47M (5)
−$6.47M
891,844
0.9324%
$3.97M
LANGER DENNIS
Director
$4.53M (10) scheduled
−$4.53M
106,802
0.1117%
$475.93K
+510.3%
Hart Jayne B.
See Remarks
$4.28M (7) scheduled
−$4.28M
172,561
0.1804%
$768.97K
+75.6%
King Gary A.
Exec. VP International Ops
$4.09M (6) scheduled
−$4.09M
148,397
0.1551%
$661.29K
+34.3%
Riggsbee Richard Bryan
Chief Financial Officer
$3.45M (8)
−$3.45M
291,812
0.3051%
$1.30M
+315.3%
HENDERSON JOHN T
Director
$276.15K (5)
$2.17M (6) scheduled
−$1.89M
78,090
0.0816%
$347.98K
+258.2%
GILBERT WALTER PHD
Director
$150.00K (1)
$1.44M (3) scheduled
−$1.29M
54,150
0.0566%
$241.30K
+333.2%
Reitan Colleen F
Director
$1.29M (1) scheduled
−$1.29M
152,030
0.1589%
$677.48K
Lambert Nicole
Chief Operating Officer
$1.13M (8)
−$1.13M
223,993
0.2342%
$998.16K
+752.6%
Phanstiel S. Louise
Director
$744.06K (4)
$1.68M (1) scheduled
−$933.68K
362,652
0.3791%
$1.62M
+26,160%
SPIEGELMAN DANIEL K
Director
$792.26K (6)
−$792.26K
32,917
0.0344%
$146.68K
Tobin Bernard
President Crescendo BioScience
$468.48K (1)
−$468.48K
160,636
0.1679%
$715.83K
+28.4%
Ford Alexander
Chief Operating Officer
$352.72K (3)
−$352.72K
169,040
0.1767%
$753.28K
+394.9%
Ancona Margaret
EVP, Strategy & Transformation
$320.99K (1)
−$320.99K
127,726
0.1335%
$569.17K
Parkinson Paul
Fmr EVP Strategy & Innovation
$295.60K (1)
−$295.60K
87,407
0.0914%
$389.50K
+13.8%
Kumar Rashmi
Director
$276.92K (2) scheduled
−$276.92K
171,889
0.1797%
$765.97K
Dreismann Heinrich
Director
$270.52K (1)
−$270.52K
231,145
0.2417%
$1.03M
+176.7%
DREISMANN HEINRICH
Director
$201.00K (1)
−$201.00K
83,527
0.0873%
$372.21K
+377.3%
Raha Samraat S.
President and CEO
$199.84K (1)
+$199.84K
1,068,083
1.12%
$4.76M
Newcomer Lee Nisley
Director
$156.86K (1)
−$156.86K
191,842
0.2006%
$854.89K
McDade Ralph L
President Myriad RBM, Inc.
$61.23K (1)
−$61.23K
142,095
0.1486%
$633.20K
+63.5%
Muzzey Dale
Chief Scientific Officer
$54.96K (1)
−$54.96K
326,310
0.3412%
$1.45M
+798.9%
Bisaro Paul
Director
$27.64K (1)
+$27.64K
157,142
0.1643%
$700.26K
Verratti Mark
Chief Operating Officer
629,646
0.6583%
$2.81M
+6,196%
Donnelly Brian J
Chief Commercial Officer
573,363
0.5994%
$2.56M
Sikri Vishal
EVP, Commercial
351,224
0.3672%
$1.57M
+275.7%
Fox Jennifer Lynne
Chief Legal Officer
305,964
0.3199%
$1.36M
Wheeler Benjamin Richard
Chief Financial Officer
289,748
0.3029%
$1.29M
+722.9%
Solaiman Shereen
Chief People Officer
267,801
0.2800%
$1.19M
Jampa Raj
Chief Technology Officer
251,889
0.2633%
$1.12M
Leffler Scott J.
Chief Financial Officer
218,393
0.2283%
$973.20K
+26,862%
Skovronsky Daniel
Director
195,507
0.2044%
$871.22K
Haas Kevin Richard
Chief Technology Officer
180,022
0.1882%
$802.21K
+454.9%
Jackson Benjamin
Former E.V.P., General Counsel
107,029
0.1119%
$476.94K
+506.4%
Davis Mark Steven
Director
106,665
0.1115%
$475.32K
Wong Pamela
Chief Legal Officer
65,002
0.0680%
$289.66K
BEST LAWRENCE C
Director
60,790
0.0636%
$270.89K
+247.4%
Santa Eric
Former Chief Growth Officer
56,734
0.0593%
$252.82K
Wenstrup Richard
Chief Medical Officer
50,207
0.0525%
$223.73K
−1.8%
Munk Natalie
Chief Accounting Officer
45,167
0.0472%
$201.27K
+77.8%
Sanders Walter Lloyd
President Myriad Oncology
36,195
0.0378%
$161.29K
−9.4%
Insider
Date
Role
Action
Shares
Price
Amount
Kumar Rashmi
8 Jun 2026
Director
Sold on a plan
15,000
$4.46
$66.84K
DIAZ PAUL J
11 Oct 2024
President and CEO
Sold on a plan
15,000
$22.93
$343.95K
DIAZ PAUL J
11 Sep 2024
President and CEO
Sold on a plan
15,000
$26.72
$400.80K
Reitan Colleen F
3 Sep 2024
Director
Sold on a plan
46,012
$27.95
$1.29M
Kumar Rashmi
19 Aug 2024
Director
Sold on a plan
7,500
$28.01
$210.08K
SPIEGELMAN DANIEL K
4 Jun 2024
Director
Sold on a plan
3,788
$22.05
$83.53K
SPIEGELMAN DANIEL K
3 Jun 2024
Director
Sold on a plan
3,788
$22.04
$83.49K
Riggsbee Richard Bryan
1 Dec 2023
Chief Financial Officer
Sold on a plan
30,000
$19.09
$572.84K
Riggsbee Richard Bryan
1 Nov 2023
Chief Financial Officer
Sold on a plan
30,000
$15.69
$470.62K

What was left out

Form 4 filings counted 561
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 9
Sales straight out of an exercise 78
Sales at will 35
Transactions with no price 0
Shares from compensation/vesting 15,232,833
Sales filed before the plan box existed 26
History held since 13 Sep 2016